Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Polaris Partners is a prominent venture capital firm founded in 1996, headquartered in Boston, Massachusetts, with additional offices in New York, San Francisco, and Singapore. The firm has successfully raised over $5 billion in committed capital across 22 funds, showcasing its robust presence in the venture capital landscape. With nearly 30 years of investing experience, Polaris has developed a strong reputation, particularly in the healthcare and life sciences sectors. The firm is led by a team of 48 professionals, including 30 partners, who bring a wealth of expertise and industry knowledge to their investment strategies. Notably, Terry McGuire, one of the founding partners, received the 2024 NVCA Venture Vanguard Award, highlighting the firm's leadership in the venture capital community.
Polaris Partners distinguishes itself through its specialized investment strategies, focusing on core venture capital for healthcare and life sciences, a growth fund for profitable B2B SaaS companies, and an innovation fund aimed at commercializing academic biomedical research. This multifaceted approach allows Polaris to effectively support a diverse range of startups and entrepreneurs, fostering innovation and growth in critical sectors. The firm has a proven track record, having backed over 400 healthcare companies and successfully brought more than 50 therapies to market, further solidifying its position as a leader in the venture capital space.
Polaris Partners operates with a clear investment focus across three specialized strategies. The first is a core venture fund dedicated to healthcare and life sciences, where the firm leverages its extensive expertise to identify and support transformative companies. The second strategy is a growth fund tailored for profitable founder-owned B2B SaaS companies, specifically those generating between $4 million and $20 million in revenue. This fund offers a unique proposition, allowing founders to retain significant ownership while accessing the capital needed for growth. Lastly, the innovation fund is designed to turn cutting-edge academic biomedical research into viable companies, bridging the gap between scientific discovery and market application.
Polaris typically invests between $10 million and $50 million across various stages, including Seed, Series A, Series B, and Growth Equity. The firm has a strong geographic focus, primarily investing in North America and Asia, with a particular emphasis on fostering cross-border biotech collaborations through initiatives like 65LAB in Singapore. This strategic focus enables Polaris to identify and nurture innovative companies that are poised to make a significant impact in their respective fields, particularly in healthcare, biotechnology, and SaaS.
Polaris Partners boasts an impressive portfolio of 412 companies, including notable investments such as Datadog, Trulia, BarkBox, and Neumora, which recently went public on NASDAQ with a valuation of $2.58 billion. The firm has achieved significant success in terms of exits, with 35 IPOs and 159 acquisitions to date, demonstrating its ability to identify and nurture high-potential startups. Among its recent investments, Polaris led a $70 million Series B round for Leyden Labs, further showcasing its active engagement in the investment landscape. Additionally, Freenome, another portfolio company, is expected to exit in December 2025, highlighting the ongoing momentum within Polaris's investment activities.
The firm's portfolio reflects a diverse range of sectors, with a strong emphasis on healthcare and technology. With six unicorns and a robust track record of successful exits, Polaris Partners continues to solidify its reputation as a leading venture capital firm, committed to supporting innovative companies that are transforming their industries.
Terry McGuire - Founding Partner, recognized with the 2024 NVCA Venture Vanguard Award for his contributions to the venture capital industry.
Amy Schulman - Managing Partner, brings extensive experience in healthcare and life sciences.
Brian Chee - Managing Partner, focuses on strategic investments and portfolio management.
Founded by Jon Flint, Terry McGuire, and Steve Arnold, the firm has a strong leadership team dedicated to fostering innovation and growth.
To pitch Polaris Partners, founders should email partnership@polarispartners.com. It is recommended to include a comprehensive overview of the business, highlighting key aspects such as the market opportunity, business model, and financial projections. Polaris is open to both warm introductions and cold applications, but a well-prepared pitch is essential for consideration.
Polaris Partners operates 65LAB in Singapore, a program designed to facilitate cross-border biotech investments. This initiative aims to bridge the gap between Asia and Europe, providing startups with access to resources and networks that can enhance their growth potential. The program supports innovative biotech companies in their journey from research to commercialization.
Recently, Polaris Partners has been active in the investment landscape, participating in significant funding rounds such as Leyden Labs' $70 million Series B. The firm continues to expand its portfolio, with five new investments made in the last 12 months, demonstrating its ongoing commitment to supporting innovative companies in healthcare and technology.
Polaris Partners invests across multiple stages, including Seed, Series A, Series B, and Growth Equity. This flexibility allows them to support companies at various points in their development, from early-stage startups to more established businesses seeking growth capital.
Founders interested in pitching Polaris Partners can reach out via email at partnership@polarispartners.com. It is advisable to provide a clear and concise overview of your business, including your value proposition, market opportunity, and financial projections.
Polaris Partners primarily focuses on healthcare, biotechnology, and software as a service (SaaS). Their investment strategies are designed to support innovative companies within these sectors, leveraging their extensive expertise and network.
Polaris Partners typically invests between $10 million and $50 million in their portfolio companies. This range allows them to provide substantial support to startups and growth-stage companies looking to scale their operations.
Polaris Partners has a strong geographic focus on North America and Asia. They also operate 65LAB in Singapore, which facilitates cross-border biotech investments, enhancing their global reach.
Polaris Partners offers extensive support to its portfolio companies, leveraging its deep industry expertise and network to help founders navigate challenges and capitalize on growth opportunities. This includes strategic guidance, operational support, and access to resources that can accelerate company development.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.